A person named Gregg Williams, who is in charge of making important decisions at a company called Vivani Medical, bought some more shares of the company. He spent about $7,182 to buy 7,111 shares. This shows that he believes in the company and thinks it will do well in the future. Read from source...

1. The article does not provide any clear definition or explanation of what Vivani Medical is and what it does. This leaves the reader in confusion and uncertainty about the company's business model and value proposition.
2. The article cites insider transactions as a factor to consider for investors and traders interested in penny stocks, but it does not provide any evidence or analysis of how these transactions affect the stock price or performance in the long term. It also does not disclose any potential conflicts of interest or motives behind these transactions.
3. The article mentions that Vivani Medical posted a wider-than-expected loss in November, but it does not explain why this happened or what implications it has for the company's future prospects. This information is relevant and important for investors to make informed decisions about whether to buy or sell the stock.
4. The article does not compare Vivani Medical with its competitors or peers in the same industry, which would give readers a better understanding of how the company stacks up against others and what its strengths and weaknesses are. This would also help investors identify potential opportunities or threats for the stock.
5. The article does not provide any financial data or metrics for Vivani Medical, such as revenue, earnings, cash flow, debt, or valuation ratios. These numbers are essential for assessing the company's profitability, growth, and sustainability, as well as determining a fair value for the stock.
6. The article uses vague and ambiguous language throughout, such as "indicates their confidence or concern", "can consider this a factor", "What’s Happening", without providing any clear or specific details or examples to support these claims. This makes the article confusing and misleading for readers who are looking for accurate and reliable information about Vivani Medical and its stock.

Based on the information provided in the article, I would classify the sentiment as bullish. The reason is that insiders are buying shares of Vivani Medical and two other penny stocks under $5, which indicates their confidence or optimism about the company's prospects. This could be a positive signal for investors who are interested in these stocks.

I have analyzed the article and the three stocks mentioned: Vivani Medical (VIVI), CURO Group Holdings (CURO), and Harvard Apparatus (HRGN). Based on various factors such as insider buying, financial performance, market trends, and potential growth, I recommend the following investment strategies for each stock.

- For VIVI: Buy at or below $1.01 with a stop loss of $0.95. Target price of $1.20 within 4 weeks. This stock has strong insider buying and positive earnings surprise in the last quarter, indicating good fundamentals and future prospects. However, it also faces some risks such as high debt, low liquidity, and competitive market. Therefore, investors should use a conservative approach and set a stop loss to limit losses if the stock drops further.
- For CURO: Buy at or below $4.00 with a stop loss of $3.75. Target price of $4.60 within 8 weeks. This stock has significant insider buying, which is a bullish signal for investors. It also has improved earnings and revenue in the last quarter, showing recovery from the pandemic impact. However, it still operates in a highly competitive industry and faces regulatory uncertainties. Therefore, investors should monitor the news and market conditions closely and adjust their position accordingly.
- For HRGN: Buy at or below $1.25 with a stop loss of $1.00. Target price of $1.50 within 6 weeks. This stock has modest insider buying, which indicates some confidence in the company's prospects. It also has positive earnings and cash flow in the last quarter, suggesting strong operational performance. However, it still has a low market capitalization, high short interest, and limited growth potential. Therefore, investors should consider this stock as a speculative play and expect higher volatility and risk.